What's new in atopic eczema? An analysis of systematic reviews published in 2015. Part 2: prevention and treatment

Lloyd-Lavery, Antonia; Rogers, Natasha K; Davies, Edward J.; Grindlay, Douglas; Kim, Thomas

doi:10.1111/ced.13554

Cited by 4 publications

(6 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is a three‐part series: Part 1 is an update on SRs on the treatment and prevention of AE, and Part 3 is an update on SRs on nomenclature and outcome assessments. Similar evidence updates on AE have been published previously, along with details of the search methods used …”

Section: Introductionmentioning

confidence: 93%

“…Similar evidence updates on AE have been published previously, along with details of the search methods used. [2][3][4] self-reported prevalence of AE in children ranged from 11.4 to 24.2%, compared with a general practitioner (GP)-diagnosed prevalence of 1.8-9.5%. Reasons for this difference may be due to overdiagnosis of AE in selfreported cases, but it is also possible that many children with mild AE do not present to their GP.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 2: Epidemiology, aetiology and risk factors

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary This review forms part of a series of annual updates that summarize the evidence base for atopic eczema (AE), providing a succinct guide for clinicians and patients. It presents the key findings from 14 systematic reviews published in 2016, focusing on AE epidemiology, aetiology and risk factors. For systematic reviews on the treatment and prevention of AE and for nomenclature and outcome assessments, see Parts 1 and 3 of this update, respectively. The annual self‐reported prevalence of AE is a range of 11.4–24.2%, compared with a general practioner‐diagnosed prevalence of 1.8–9.5%. The mean age of AE diagnosis is 1.6 years. Persistent AE is associated with more severe disease at the time of diagnosis, onset after the age of 2 years and female sex. There is a significant association between having AE and subsequent development of food allergy. Food allergy is also associated with more severe and persistent AE. No consistent association was found between the timing of allergenic food introduction and the risk of developing AE. Evidence from heterogeneous studies indicates that skin absorption is increased in patients with AE, and that there is increased colonization with Staphylococcus aureus in lesional and nonlesional skin and the nasal mucosa of patients with AE compared with controls. There is uncertain evidence indicating an association between AE and smoking exposure, antenatal infection and low maternal vitamin D levels during pregnancy. Weak evidence suggests an increased risk of basal cell carcinoma, but not of melanoma or squamous cell carcinoma, while the risk of glioma is reduced.

show abstract

Section: Introductionmentioning

confidence: 93%

Section: Introductionmentioning

confidence: 99%

What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 2: Epidemiology, aetiology and risk factors

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…For SRs on epidemiology, aetiology and risk factors, see Part 2 of this update, and for nomenclature and outcome assessments, see Part 3. Similar evidence updates have been published previously, along with the search strategy details …”

Section: Introductionmentioning

confidence: 88%

“…Similar evidence updates have been published previously, along with the search strategy details. [2][3][4]…”

Section: Introductionmentioning

confidence: 99%

What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 1: treatment and prevention

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary This review is part of a series of annual updates summarizing the evidence base for atopic eczema (AE). It provides a summary of key findings from 28 systematic reviews that were published or indexed during 2016 with a focus on treatment and prevention of AE. There is reasonable evidence of benefit for topical corticosteroids, calcineurin inhibitors, a glycyrrhetinic acid‐containing preparation (Atopiclair®), oral ciclosporin, oral azathioprine, narrowband ultraviolet B radiation and education programmes. Overall, there is evidence that topical corticosteroids and calcineurin inhibitors have similar efficacy and that both can prevent AE flares when used twice weekly as maintenance therapy. However, topical calcineurin inhibitors are costlier and have more adverse reactions, thus topical corticosteroids should remain the standard of care for patients with AE. There is no evidence that multiple applications are better than once‐daily application of topical corticosteroid. There is inconsistent evidence to support omalizumab and specific allergen immunotherapy use in AE. There is some evidence that vitamin D supplementation and synbiotics reduce AE severity, although the margin of improvement may not be clinically meaningful. There is little evidence to support the use of wet wraps or of complementary/alternative medicine (including Chinese herbal medicine). There is some evidence to suggest that a diet high in fish in infancy may be preventative for AE, but other dietary interventions for the prevention of AE show little promise. This review provides a succinct guide for clinicians and patients wishing to remain up to date with the latest evidence for the treatment and prevention of AE.

show abstract

“…For an update of SRs on the treatment and prevention of AE and for SRs on AE epidemiology, aetiology and risk factors, see Parts 1 and 2 of this update, respectively. Similar evidence updates on AE have been published previously, along with details of the search methods used …”

Section: Introductionmentioning

confidence: 93%

What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 3: nomenclature and outcome assessment

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary This review forms part of a series of annual updates that summarize the evidence base for atopic eczema (AE). It presents the key findings from 11 systematic reviews published in 2016 that focus on AE outcome assessment, disease impact and nomenclature. Systematic reviews on the treatment and prevention of AE are summarized in Part 1 of this update, and systematic reviews on the epidemiology of and risk factors for AE are summarized in Part 2. Six reviews summarized what outcome measurement instruments have been used in published AE trials, or summarized validation studies for the available instruments. These reviews were used to inform consensus decisions by the Harmonising Outcome Measures for Eczema initiative. Although validated instruments exist for clinical signs and patient‐reported symptoms, there are currently no validated instruments for capturing quality of life or long‐term control. Four reviews examined the impact of AE on children and their families, but few studies were included. One birth cohort study found no association between AE and educational attainment at 11 years. AE has a moderate impact on health‐related quality of life and a substantial impact on family life. AE is a major risk factor for occupational hand dermatitis, and it is advised that young atopic individuals are informed about high‐risk occupations. Further efforts are required to standardize the nomenclature for AE, which is also commonly known as ‘atopic dermatitis’ or ‘eczema’, and preferred terms vary around the world.

show abstract

What's new in atopic eczema? An analysis of systematic reviews published in 2015. Part 2: prevention and treatment

Cited by 4 publications

References 28 publications

What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 2: Epidemiology, aetiology and risk factors

What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 2: Epidemiology, aetiology and risk factors

What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 1: treatment and prevention

What's new in atopic eczema? An analysis of systematic reviews published in 2016. Part 3: nomenclature and outcome assessment

Contact Info

Product

Resources

About